According to data presented at EADV, at week 16 of the phase 2 study, 47.8% to 62.5% of adults receiving tilrekimig achieved EASI 75 across doses, compared with 9.1% to 19.9% with placebo.
|Articles|July 12, 2016
Why do people with long hair lose more hair?
It appears that patients with long hair are more often concerned about hair loss.
Advertisement
Why do people with long hair lose more hair?
It appears that patients with long hair are more often concerned about hair loss. They will bring a bag full of shed hair and look at the bag with horror as they give it to the dermatologist for evaluation. In this case, it is very important for the dermatologist to remove the hair from the bag and examine the roots of the hair. Only the number of shed hairs can be assessed, not the amount of hair, due to the shaft length. People with long hair do not necessarily loose more hair, they just appear to loose more hair due to the hair shaft length. Hair length does not affect shedding.
Advertisement
Related to this article
AbbVie reports F-VASI 75 of 55.1% in Viti-Up-1 and 47.4% in Viti-Up-2 at week 76 among patients continuing upadacitinib, with numerically higher responses alongside NB-UVB.
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Day 1 of EADV 2026 brought new data across atopic dermatitis, cutaneous lupus, skin cancer, AI, climate-related skin disease, and more.
Advertisement
Advertisement
Trending on Dermatology Times
1
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
2
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
3
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
4
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
5